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ABSTRACT 
Background/aims: Fatigue is recognised as a common and burdensome symptom 
among dialysis patients. A growing body of research is devoted to understanding 
fatigue in advanced kidney disease, yet its measurement is challenging within this 
context. Our aim was to evaluate the factor structure underlying the Multidimensional 
Fatigue Inventory (MFI-20) and to examine associations with clinical factors and 
mood. 
Methods: Data was evaluated for confirmatory factor analysis (CFA) from the 
screening phase of a multicentre randomised placebo-controlled trial of sertraline in 
HD patients. 470 patients completed the MFI-20, which purports to measure five 
components of fatigue (general, mental and physical fatigue, reduced motivation and 
reduced activity). CFA models were evaluated in MPlus 7.3 using Robust Maximum 
Likelihood (MLR) estimation.  
Results: Evaluation of the original five factors revealed low internal reliability for the 
general factor and reduced activity, and high intercorrelations between all sum scores. 
CFA revealed poor model fit for the original 5-factor MFI-20 model (CFI=0.738; 
TLI= 0.689; RMSEA= 0.101). Alternative models, including 1, 3 and bi-factor 
models all demonstrated poor fit to the data. No reliable factor model was confirmed 
prohibiting the examination of factors associated with fatigue. 
Conclusions: We were not able to confirm the factor structure of the MFI-20 in a 
large sample of HD patients. Certain items may lack suitable face validity in this 
context.  
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INTRODUCTION: 
 Fatigue is a burdensome and common symptom in patients with End-Stage 
Kidney Failure (ESKF) which is associated with poor outcomes [1], including 
survival [2]. Accordingly, there is growing recognition regarding the importance of 
understanding fatigue in ESKF [3-5] and developing evidence based interventions to 
ameliorate symptoms. It is important however, that the measurement of fatigue is 
thoroughly evaluated to ensure the reliability and validity of study findings [1,6]. 
Estimates of fatigue in ESKF vary across studies partly due to different self-
report fatigue severity being used [1]. In psychometric analysis, a technique call 
Confirmatory Factor Analysis (CFA) is commonly used to examine the underlying 
structure of a questionnaire, that is, to evaluate the number of purported factors a 
questionnaire has. CFAs are known as measurement models in that they describe how 
observed variables (called indicators or items) measure underlying directly 
unobservable constructs (called latent factors or just factors). CFA is employed to test 
how well the latent factors explain observed variables (i.e. how well the model fits the 
data). CFA differs from exploratory factor analysis (EFA) because in CFA the 
researcher has an idea of the proposed measurement structure and seeks to confirm 
that structure. Accordingly, CFA allows researchers to evaluate the structural validity 
of a measure.  
Fatigue has been described as a multifactorial problem, yet many 
multidimensional self report measures are in fact sufficiently unidimensional to 
warrant use of a total score (i.e. the sum of all of items to form one severity score) as 
a reliable measure of general fatigue severity [7]. For example, we recently showed in 
both renal [8] and multiple sclerosis [6] populations that the Chalder Fatigue 
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Questionnaire is suitably unidimensional to warrant a total severity score, rather than 
consisting of separate subfactors  for “mental” and “physical” fatigue.  
A growing number of studies, including renal samples [9,10], have used the 
Multidimensional Fatigue Inventory (MFI-20) [11] to evaluate five proposed 
components (i.e. factors) of fatigue, namely: general fatigue, mental and physical 
fatigue, reduced motivation and reduced activity. In this measure, each of the factors 
are measured by four items which are summed, with higher scores on each 
representing great severity of that construct. Studies in other long-term conditions 
[11-14] and general population samples [15] have supported the factor structure of the 
MFI-20 [11], suggesting it measures these five related constructs (or components) of 
fatigue.  However, no study to date has examined the factor structure of the MFI-20, 
using CFA, in a sample of ESKF on haemodialysis (HD). Our study objective was to 
test the MFI-20’s factor structure (i.e. does it measure five factors of fatigue?) in a 
large UK sample of HD patients, and if supported, examine the associations 
(correlates) with depression symptoms, demographic and clinical factors. 
 
METHODS: 
 Design: The present study utilises screening data to select patients into a 
multicentre placebo controlled feasibility randomised control trial (RCT) of sertraline 
in HD patients with mild to moderate Major Depressive Disorder. The full RCT 
protocol (trial registration number: ISRCTN06146268) [16], and the outcome paper 
[17], have been published elsewhere. Screening occurred in 709 HD patients of which 
a subsample (n=470) completed the MFI-20. Ethical approval was granted from the 
National Health Service ethics committee. 
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 Patients: The study recruited HD patient across five UK dialysis centers. All 
patients that had been receiving HD treatment for a minimum of 3 months and could 
speak and read English well enough to complete the questionnaires were eligible to be 
screened. For full details of the original RCT, see [16]. 
 
 Fatigue measure: Fatigue was assessed using the Multidimensional Fatigue 
Inventory (MFI-20) [11]. The MFI-20 contains a total of 20 items, purporting to 
measure five factors; general (items 1, 5, 12, 16), mental (items 7, 11, 13, 19) and 
physical fatigue (items 2, 8, 14, 20), reduced motivation (items 4, 9, 15, 18) and 
reduced activity (items 3, 6, 10, 17). Each factor contains 4-items and is scored on a 5 
point Likert type scale, where participants rate each item according to their agreement 
(“yes, that is true" to disagreement "no, that is not true"). Items scores are summed to 
create a sum score for each of the five factors. Items 2, 5, 9, 10, 13, 14, 16-19 were 
recoded so that higher scores represent more fatigue.  
 
 Depression Measures: Depression symptoms were measured using two 
validated screening tools, 1) Beck Depression Inventory-II (BDI-II) [18] and 2) 
Patient Health Questionnaire-9 (PHQ-9) [19]. These measures have been shown to 
perform well in HD patients [20-22]. 
  
Clinical and demographic factors: Clinical data was collected from medical 
records, which included the comorbidities (presence of diabetes, heart disease, stroke, 
cancer, limb amputation, liver disease, lung disease), dialysis vintage (length of time 
on dialysis; months), haemoglobin (g/L), serum albumin (g/L) and dialysis treatment 
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adequacy (Kt/V). C-reactive protein (CRP, mg/L) was available in 213 patients. 
Demographic information was collected through a self-report questionnaire. 
 
 Statistical methods: The factor structure of the MFI-20 was examined using 
CFA in MPlus 7.3. Competing factor models for the MFI-20 (i.e. different factor 
solutions) were estimated using Robust Maximum Likelihood Estimation (MLR) 
since item responses were slightly skewed. Missing data was minimal with 1% or less 
data missing for each item, corresponding to 0.09% of missing data across the entire 
MFI-20 dataset.  
The original 5-factor model was tested along with a 1-factor models (with all 
20 items loaded onto one general factor) and a bi-factor model. In the bi-factor model, 
all 20 items were loaded onto a general fatigue factor. In addition, respective items 
were also loaded five group factors (i.e. the original 5-factors), with correlations 
between each of these latent factors fixed to zero, and variances of the latent factors 
fixed to 1.  
In CFA, a non-significant chi-square is desired which suggests that the 
reproduced and observed model covariance matrixes do not differ significantly 
meaning that the data fits the proposed model structure. However the chi-square 
statistic is sensitive to sample size [23] and therefore should not be used alone to 
determine the appropriateness of model fit. Accordingly, assessment of goodness-of-
fit based on standard criteria was also examined. The following fit statistics and their 
standard cut-offs (used to indicate adequate fit) were evaluated: the root mean squared 
error of approximation (RMSEA) <.08, confirmatory fit index (CFI) >.95, and 
Tucker-Lewis index (TLI) >.95 [24].  
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RESULTS: 
Patient sample characteristics: 
The mean age of the sample was 63.8 (16.6) years (median=67; interquartile 
range=25), with most patients white (n=292; 62.1%) and male (n=307; 65.3%). The 
median time on dialysis was 22 months (interquartile range= 42; min=3; max=495). 
Comorbidity and clinical data was representative of a dialysis population. Heart 
disease and diabetes was present in 140 (29.8%) and 166 (35.3%) of patients 
respectively. 45 patients (9.6%) had cancer, 14 (3%) liver disease and 30 (6.4%) lung 
disease.  
Mean dialysis adequacy (Kt/V) was 1.5 (0.3). Mean haemoglobin and serum 
albumin levels were 11.7 (1.3) g/L and 37.4 (4.7) g/L respectively. Median CRP was 
5.0 (interquartile range= 13) mg/L.  
Mean depression scores on the BDI and PHQ-9 were 13.4 (s.d=11.1) and 6.9 
(s.d=6.2) respectively.  
 
Summary of the MFI-20 sum scores:  
Figure 1 displays the MFI-20 individual item means (95% confidence 
intervals). Means, intercorrelations and internal reliabilities for the original five MFI-
20 sum scores are shown in table 1. Both the general and reduced activity had poor 
internal reliabilities, since Cronbach’s alpha were some way below 0.7. 
Intercorrelations revealed a strong association between the general fatigue factor with 
both reduced activity and reduced motivation (rs > 0.90, ps<0.01), casting doubt 
about the uniqueness of this factors as distinct constructs since they share a 
significantly large amount of variance. Furthermore, both reduced activity and 
Factor structure of the MFI-20 in HD patients	
	 8	
motivation correlated very highly (r=0.97, p<0.01). The MFI-20 total score (sum 
score of all 20-items) did have good internal reliability (a=.89).  
 
Confirmatory factor analysis (CFA): 
 CFA revealed that the original 5-factor model had poor model fit (model a, 
table 2), as evidenced by inadequate fit criteria. In order to try and specify which 
items/factors could be contributing to this poor fit, five separate CFAs for each 
individual factor were evaluated independently. None of the individual factors 
analyzed separately demonstrated suitable fit as indicated by the fit indices (see table 
2) and all had significant chi-square statistics (ps> 0.05).  
 An alternative 1-factor model, with all items loaded onto one general factor 
indicating a total score (model b, table 2) had poor fit, as did a bi-factor model (model 
c). Given these poor model fits, and the high correlations between the general fatigue 
factor with both reduced activity and reduced motivation, an additional 3-factor 
model was tested where both reduced activity and motivation items were loaded onto 
the general fatigue factor. This 3-factor model also revealed poor model fit (model d, 
table 2). Due to the unreliability of the factor structure, it was not appropriate to 
examine factor correlations (convergent validity) with depression, demographic and 
clinical factors since no valid latent fatigue dimensions were determined from the 
CFA. 
Sensitivity of the estimator (MLR) 
Given the poor model fit, all CFA models were rerun using an alternative 
estimator; Weighted Least-Squares with mean and variance adjustment (WLSMV). 
WLSMV produces unbiased, consistent and efficient parameter estimates and 
standard errors where ordinal responses are used [25]. All the factor models described 
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in table 2 produced similar results when using the WLSMV estimator. For example, 
the original five factor model (CFI=0.86; TLI=0.82; RMSEA=0.12) and bi-factor 
model (CFI=0.81; TLI=0.78; RMSEA=0.14) displayed poor model fit. Fit was also 
poor for all the alternative CFA models tested.  
 
DISCUSSION 
 The present study aimed to evaluate the factor structure of the MFI-20, a 
commonly used self-report fatigue measure which was originally designed to measure 
five constructs or components of fatigue. There is considerable recognition regarding 
the importance of understanding the fatigue within ESKF, given its adverse effects 
upon outcomes [1]. However, the most appropriate tools to measure self reported 
fatigue within dialysis patients remains unknown [5]. Understanding which tool has 
the most robust psychometric properties is important if we are to select the most 
suitable tool in studies that measure fatigue as either an outcome or as a predictor of 
outcomes.  
We found that the correlations between the original five sum scores were high, 
which casts doubt about the uniqueness of this factors as distinct constructs since they 
share a significantly large amount of variance (table 1). Furthermore, two factors 
(general and reduced activity) had poor internal reliability, suggesting a lack of 
consistency (low item correlations) between the items of these factors. 
 Confirmatory factor models testing the original five-factor MFI-20 model 
structure proved to have poor model fit, suggesting that the purported MFI-20 factor 
is not supported in HD patients.  Alternative CFA models including a bi-factor model 
and a 3 factor model also had poor model fit (table 2). Therefore, our analysis failed 
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to support a reliable factor structure of the MFI-20 as applied to HD patients, 
suggesting that this measure has low validity in this setting. 	 The lack of a reliable factor structure maybe the result of comprehension 
difficulties in HD patients [9] , high item and factor correlations and potentially low 
face validity for some items. Although no formal evaluation of face validity was 
conducted as part of this study, several items appear potentially problematic as 
indicators of fatigue. For example “I think I do very little in a day” (item 10), “I feel 
fit” (item 1) and “I am rested” (item 12) are likely to relate to the high morbidity 
observed in the dialysis population, rather than fatigue per se. Item 20 “Physically I 
feel I am in an excellent condition” also appears to be related more to a general 
reflection about health status. Accordingly, detailed evaluation of the face validity of 
the MFI-20 in dialysis patients should be encouraged, including both patient and 
health care professional input. As indicated elsewhere, tailoring MFI-20 items 
responses could improve comprehension [9] and ultimately improve the content 
validity.  
Other reasons for the poor model fit observed here may be because the MFI-
20 attempts to measure multiple components of fatigue (severity, consequences and 
antecedent factors), which is likely complicated in dialysis patients due to the high 
prevalence of depressive symptoms [26], co-morbidities, inflammation and varied 
post dialysis recovery between individuals.  
 Our results conflict with past studies supporting the factor structure of MFI-20 
across a range of settings [11-13]. Some of these studies however relied upon 
relatively small samples sizes and exploratory factor analytic methods [13,14], which 
may account for discrepancies between study findings. Others have failed to confirm 
the original factor structure in cancer patients, suggesting instead a modified 3-factor 
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model, albeit with marginal fit (CFI=0.882; RMSEA=0.079). Given the difference 
between patient samples and analytic methods used, a meta-confirmatory factor 
analysis of the MFI-20 may be useful to further evaluate the measures structural 
validity. Given the importance of understanding fatigue in ESKF further efforts to 
establish which current measures provide the best validity and reliability are needed, 
and potentially a renal specific fatigue tool developed.  
 
Study limitations 
 As discussed, the lack of a structured evaluation of face validity is a limitation 
of our study. We did not plan to perform a full psychometric analysis, so re-test 
reliability (i.e. correlational performance over time) and convergent validity 
(correlational strengthen with another fatigue measure) were not assessed. We 
therefore encourage a full psychometric evaluation of the MFI-20 in kidney patients, 
in order to evaluate its measurement properties further.  However, establishing a 
reliable factor structure is often a prerequisite for additional psychometric analysis.  
With regards to our sample it was representative in terms of age (median=67) 
and comorbidity profile to the UK HD population [27,28]. However, dialysis vintage 
was relatively low (median=22 months), although we do not expect this to impact 
upon our findings since this is unlikely to lead to model invariance and there is mixed 
findings regarding the association between dialysis vintage and fatigue severity [1]. 
Conclusions 
 To conclude, we were not able to confirm the factor structure of the MFI-20 in 
a large sample of HD patients. It is possible that certain items lack suitable face 
validity in this context. Currently, the factor structure of the MFI-20 in dialysis 
patients remains questionable.  
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Table 1: Means, intercorrelations and internal reliabilities for the MFI-20 sum scores.  
 
   MFI-20 Sum scores  
(correlation matrix) 
MFI-20 sum scores 
 
Mean 
(s.d.) 
Cronbach’s 
alpha 
1 2 3 4 
1. General 13.1 (4.0) .66 1    
2. Physical 14.5 (4.2) .71 .670** 1   
3. Mental 9.6 (4.4) .73 .458** .351** 1  
4. Reduced Activity 13.1 (4.0) .55 .983** .647** .445** 1 
5. Reduced Motivation 13.2 (4.2) .75 .958** .642** .432** .965** 
**p<0.01 
S.D = Standard deviation 
Cronbach’s alpha = measure of internal reliability  
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Table 2: Summary of MFI-20 confirmatory factor models 
 
 
Root Mean Squared Error of Approximation (RMSEA); Confirmatory Fit Index 
(CFI); Tucker-Lewis index (TLI). 
Degrees of Freedom (df). 
aEach factor of the original MFI-20 was analyzed in independent models. 
 
 
 
 
 
Model  Description No of free 
parameters 
Chi-square (df), p-value CFI TLI RMSEA 
A Original 5 factor 70 919.8 (160), p<0.01 0.738 0.689 0.101 
B 1-factor 60 1181.2 (170), p<0.01 0.652 0.611 0.112 
C Bi-factor 74 912.4 (156), p<0.01 0.739 0.683 0.102 
D 3-factor 63 985.0 (167), p<0.01 0.718 0.679 0.102 
Original 5-factorsa      
General 12 25.6 (2), p<0.01 0.892 0.677 0.159 
Physical 12 16.2 (2), p<0.01 0.941 0.822 0.123 
Mental 12 33.5 (2), p<0.01 0.889 0.668 0.182 
Reduced activity 12 23.2 (2), p<0.01 0.930 0.789 0.150 
Reduced motivation 12 73.4 (2), p<0.01 0.485 0.546 0.276 
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Figure 1: MFI-20 individual item score means with 95% confidence intervals for the 
item means 
 
 
 
